APO RESEARCH · REPORT
Deferasirox
Deferasirox is an oral iron chelator. Its main use is to reduce chronic iron overload in patients who are receiving long-term blood transfusions for conditions such as beta- thalassemia and other chronic anemias.
Product & engineering
Understand the product.
Deferasirox is an oral iron chelator. Its main use is to reduce chronic iron overload in patients who are receiving long-term blood transfusions for conditions such as beta- thalassemia and other chronic anemias.
Deferasirox is marketed as Exjade, Desirox, Defrijet, Desifer, and Jadenu.
The half-life of deferasirox is between 8 and 16 hours allowing once a day dosing. Two molecules of deferasirox are capable of binding to 1 atom of iron which is subsequently eliminated by fecal excretion. Its low molecular weight and high lipophilicity allows the drug to be taken orally unlike deferoxamine which has to be administered by IV route (intravenous infusion). Together with deferiprone, deferasirox seems to be capable of removing iron from cells (cardiac myocytes and hepatocytes) as well as removing iron from the blood.
Selected research
Industry Growth & Trends
Global Deferasirox Industry Growth and Trends Forecast to 2032
Market perspective
Deferasirox is an oral iron chelator. Its main use is to reduce chronic iron overload in patients who are receiving long-term blood transfusions for conditions such as beta- thalassemia and other chronic anemias.
Deferasirox is marketed as Exjade, Desirox, Defrijet, Desifer, and Jadenu.
The half-life of deferasirox is between 8 and 16 hours allowing once a day dosing. Two molecules of deferasirox are capable of binding to 1 atom of iron which is subsequently eliminated by fecal excretion. Its low molecular weight and high lipophilicity allows the drug to be taken orally unlike deferoxamine which has to be administered by IV route (intravenous infusion). Together with deferiprone, deferasirox seems to be capable of removing iron from cells (cardiac myocytes and hepatocytes) as well as removing iron from the blood.
Read the full market overview
The major global manufacturers of Dillaros are Novartis, Cipla, Natco Pharma and Sun Pharma, among which Novartis is the industry leader with a market share of around 99%. North America is the largest spending region, with 30 per cent of the market, followed by Europe with 25 per cent.
Report Scope
This report provides a structured, data-driven view of the global Deferasirox market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Deferasirox market size, estimates, and forecasts are presented in terms of sales volume (M Tablets) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Deferasirox market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Deferasirox.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading manufacturers in the global Deferasirox market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Deferasirox Market by Company
Novartis
Cipla
Natco Pharma
Sun Pharma
Deferasirox Segment by Type
500 mg/Tablet
250 mg/Tablet
125 mg/Tablet
Others
Deferasirox Segment by Application
Transfusional Iron Overload
NTDT Caused Iron Overload
Deferasirox Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Deferasirox market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Deferasirox and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Deferasirox.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Deferasirox manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Sales, revenue of Deferasirox in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.
Chapter 13: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- 500 mg/Tablet
- 250 mg/Tablet
- 125 mg/Tablet
- Others
Applications
- Transfusional Iron Overload
- NTDT Caused Iron Overload
Companies covered
- Novartis
- Cipla
- Natco Pharma
- Sun Pharma
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global Deferasirox Market Size Estimates and Forecasts (2021-2032)
- 1.2.2 Global Deferasirox Sales Estimates and Forecasts (2021-2032)
- 1.3 Deferasirox Market by Type
- 1.3.1 500 mg/Tablet
- 1.3.2 250 mg/Tablet
- 1.3.3 125 mg/Tablet
- 1.3.4 Others
- 1.4 Global Deferasirox Market Size by Type
- 1.4.1 Global Deferasirox Market Size Overview by Type (2021-2032)
- 1.4.2 Global Deferasirox Historic Market Size Review by Type (2021-2026)
- 1.4.3 Global Deferasirox Forecasted Market Size by Type (2027-2032)
- 1.5 Key Regions Market Size by Type
- 1.5.1 North America Deferasirox Sales Breakdown by Type (2021-2026)
- 1.5.2 Europe Deferasirox Sales Breakdown by Type (2021-2026)
- 1.5.3 Asia-Pacific Deferasirox Sales Breakdown by Type (2021-2026)
- 1.5.4 South America Deferasirox Sales Breakdown by Type (2021-2026)
- 1.5.5 Middle East and Africa Deferasirox Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
- 2.1 Deferasirox Industry Trends
- 2.2 Deferasirox Industry Drivers
- 2.3 Deferasirox Industry Opportunities and Challenges
- 2.4 Deferasirox Industry Restraints
3 Market Competitive Landscape by Company
- 3.1 Global Top Players by Deferasirox Revenue (2021-2026)
- 3.2 Global Top Players by Deferasirox Sales (2021-2026)
- 3.3 Global Top Players by Deferasirox Price (2021-2026)
- 3.4 Global Deferasirox Industry Company Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Deferasirox Major Company Production Sites & Headquarters
- 3.6 Global Deferasirox Company, Product Type & Application
- 3.7 Global Deferasirox Company Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Deferasirox Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Deferasirox Players Market Share by Revenue in 2025
- 3.8.3 2025 Deferasirox Tier 1, Tier 2, and Tier 3
4 Deferasirox Regional Status and Outlook
- 4.1 Global Deferasirox Market Size and CAGR by Region: 2021 VS 2025 VS 2032
- 4.2 Global Deferasirox Historic Market Size by Region
- 4.2.1 Global Deferasirox Sales in Volume by Region (2021-2026)
- 4.2.2 Global Deferasirox Sales in Value by Region (2021-2026)
- 4.2.3 Global Deferasirox Sales (Volume & Value), Price and Gross Margin (2021-2026)
- 4.3 Global Deferasirox Forecasted Market Size by Region
- 4.3.1 Global Deferasirox Sales in Volume by Region (2027-2032)
- 4.3.2 Global Deferasirox Sales in Value by Region (2027-2032)
- 4.3.3 Global Deferasirox Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Deferasirox by Application
- 5.1 Deferasirox Market by Application
- 5.1.1 Transfusional Iron Overload
- 5.1.2 NTDT Caused Iron Overload
- 5.2 Global Deferasirox Market Size by Application
- 5.2.1 Global Deferasirox Market Size Overview by Application (2021-2032)
- 5.2.2 Global Deferasirox Historic Market Size Review by Application (2021-2026)
- 5.2.3 Global Deferasirox Forecasted Market Size by Application (2027-2032)
- 5.3 Key Regions Market Size by Application
- 5.3.1 North America Deferasirox Sales Breakdown by Application (2021-2026)
- 5.3.2 Europe Deferasirox Sales Breakdown by Application (2021-2026)
- 5.3.3 Asia-Pacific Deferasirox Sales Breakdown by Application (2021-2026)
- 5.3.4 South America Deferasirox Sales Breakdown by Application (2021-2026)
- 5.3.5 Middle East and Africa Deferasirox Sales Breakdown by Application (2021-2026)
6 Company Profiles
- 6.1 Novartis
- 6.1.1 Novartis Company Information
- 6.1.2 Novartis Business Overview
- 6.1.3 Novartis Deferasirox Sales, Revenue and Gross Margin (2021-2026)
- 6.1.4 Novartis Deferasirox Product Portfolio
- 6.1.5 Novartis Recent Developments
- 6.2 Cipla
- 6.2.1 Cipla Company Information
- 6.2.2 Cipla Business Overview
- 6.2.3 Cipla Deferasirox Sales, Revenue and Gross Margin (2021-2026)
- 6.2.4 Cipla Deferasirox Product Portfolio
- 6.2.5 Cipla Recent Developments
- 6.3 Natco Pharma
- 6.3.1 Natco Pharma Company Information
- 6.3.2 Natco Pharma Business Overview
- 6.3.3 Natco Pharma Deferasirox Sales, Revenue and Gross Margin (2021-2026)
- 6.3.4 Natco Pharma Deferasirox Product Portfolio
- 6.3.5 Natco Pharma Recent Developments
- 6.4 Sun Pharma
- 6.4.1 Sun Pharma Company Information
- 6.4.2 Sun Pharma Business Overview
- 6.4.3 Sun Pharma Deferasirox Sales, Revenue and Gross Margin (2021-2026)
- 6.4.4 Sun Pharma Deferasirox Product Portfolio
- 6.4.5 Sun Pharma Recent Developments
7 North America by Country
- 7.1 North America Deferasirox Sales by Country
- 7.1.1 North America Deferasirox Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.1.2 North America Deferasirox Sales by Country (2021-2026)
- 7.1.3 North America Deferasirox Sales Forecast by Country (2027-2032)
- 7.2 North America Deferasirox Market Size by Country
- 7.2.1 North America Deferasirox Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2.2 North America Deferasirox Market Size by Country (2021-2026)
- 7.2.3 North America Deferasirox Market Size Forecast by Country (2027-2032)
8 Europe by Country
- 8.1 Europe Deferasirox Sales by Country
- 8.1.1 Europe Deferasirox Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.1.2 Europe Deferasirox Sales by Country (2021-2026)
- 8.1.3 Europe Deferasirox Sales Forecast by Country (2027-2032)
- 8.2 Europe Deferasirox Market Size by Country
- 8.2.1 Europe Deferasirox Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2.2 Europe Deferasirox Market Size by Country (2021-2026)
- 8.2.3 Europe Deferasirox Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
- 9.1 Asia-Pacific Deferasirox Sales by Country
- 9.1.1 Asia-Pacific Deferasirox Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.1.2 Asia-Pacific Deferasirox Sales by Country (2021-2026)
- 9.1.3 Asia-Pacific Deferasirox Sales Forecast by Country (2027-2032)
- 9.2 Asia-Pacific Deferasirox Market Size by Country
- 9.2.1 Asia-Pacific Deferasirox Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2.2 Asia-Pacific Deferasirox Market Size by Country (2021-2026)
- 9.2.3 Asia-Pacific Deferasirox Market Size Forecast by Country (2027-2032)
10 South America by Country
- 10.1 South America Deferasirox Sales by Country
- 10.1.1 South America Deferasirox Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.1.2 South America Deferasirox Sales by Country (2021-2026)
- 10.1.3 South America Deferasirox Sales Forecast by Country (2027-2032)
- 10.2 South America Deferasirox Market Size by Country
- 10.2.1 South America Deferasirox Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2.2 South America Deferasirox Market Size by Country (2021-2026)
- 10.2.3 South America Deferasirox Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
- 11.1 Middle East and Africa Deferasirox Sales by Country
- 11.1.1 Middle East and Africa Deferasirox Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.1.2 Middle East and Africa Deferasirox Sales by Country (2021-2026)
- 11.1.3 Middle East and Africa Deferasirox Sales Forecast by Country (2027-2032)
- 11.2 Middle East and Africa Deferasirox Market Size by Country
- 11.2.1 Middle East and Africa Deferasirox Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2.2 Middle East and Africa Deferasirox Market Size by Country (2021-2026)
- 11.2.3 Middle East and Africa Deferasirox Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
- 12.1 Deferasirox Value Chain Analysis
- 12.1.1 Deferasirox Key Raw Materials
- 12.1.2 Key Raw Materials Price
- 12.1.3 Raw Materials Key Suppliers
- 12.1.4 Manufacturing Cost Structure
- 12.1.5 Deferasirox Production Mode & Process
- 12.2 Deferasirox Sales Channels Analysis
- 12.2.1 Direct Comparison with Distribution Share
- 12.2.2 Deferasirox Distributors
- 12.2.3 Deferasirox Customers
13 Concluding Insights
14 Appendix
- 14.1 Reasons for Doing This Study
- 14.2 Research Methodology
- 14.3 Research Process
- 14.4 Authors List of This Report
- 14.5 Data Source
- 14.5.1 Secondary Sources
- 14.5.2 Primary Sources
- 14.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst